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Abstract 
Aim: This study sought to evaluate how Australian veterinarians approach management 
and monitoring of feline hyperthyroidism and compare these results to a similar survey 
recently performed in the United Kingdom (UK).  
 
Method: An invitation to complete an online survey was sent to veterinarians in all 
states and territories of Australia. The survey comprised questions relating to management 
of hyperthyroidism, use of anti-thyroid drugs v radioiodine treatment v surgical 
thyroidectomy, in addition to demographic information for respondents.  
 
Results:  A total of 546 clinicians completed the survey. The most commonly 
preferred treatments for long-term management of feline hyperthyroidism were anti-thyroid 
medications (305/546; 56%) and radioiodine (210/546; 38%), with substantially more 
respondents selecting radioiodine when cost was removed as a consideration (425/546; 
78%). However, most respondents had treated or referred few cases for radioiodine (median 
2). Most veterinarians (500/546; 92%) used anti-thyroid medications either long-term or 
prior to definitive treatment of hyperthyroidism. For medical management, 45% (244/546) 
of veterinarians used twice daily carbimazole. Half of respondents (274/546) aimed to 
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maintain the total T4 concentration anywhere within the laboratory reference interval (RI) 
in hyperthyroid cats without chronic kidney disease. Blood pressure monitoring was 
uncommon. Surgical thyroidectomy was rarely performed. 
  
Conclusions: Radioiodine was more frequently preferred by Australian veterinarians 
compared to those in the UK, likely associated with greater availability, reduced cost and 
shorter hospitalisation times in this jurisdiction, though anti-thyroid medications were the 
most frequently used treatment modality. Barriers remain to its utilisation, however, 
including perceived cost, misconceptions with regard to expected success rate and 
accessibility. Recent changes to recommendations on the management and monitoring of 
hyperthyroid cats do not appear to have been widely adopted by veterinarians at this time.  
 
Keywords: Hyperthyroidism, cats, feline, survey, veterinarians, Australian, thyroid, 
methimazole, carbimazole, radioiodine 
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Introduction 
Hyperthyroidism, first described in cats in 1979, is the most common feline endocrinopathy 
in most developed nations.1,2 Recognised options for management of feline 
hyperthyroidism include administration of radioiodine, chronic daily dosing with anti-
thyroid medication (orally or transdermally) and surgical thyroidectomy.1 More recently, an 
iodine-restricted prescription diet has become available in certain countries.3 
 
Radioiodine is regarded as the gold standard treatment, with advantages including: (i) 
potential for curative treatment, with approximately 94% of cats cured following a single 
treatment,4 (ii) efficacy independent of location and type of hyperfunctional thyroid tissue, 
(iii) longer median survival compared to cats treated with anti-thyroid drugs, (iv) superior 
cost effectiveness for cats surviving beyond one year following diagnosis compared with 
anti-thyroid drugs and (v) safety, with minimal adverse effects and no requirement for 
general anaesthesia or even sedation in most instances.4-8 However, restricted accessibility 
and requirement for hospitalisation can represent potential barriers to radioiodine use.7,9 
Curative success of thyroidectomy is dependent on the location of hyperfunctional thyroid 
tissue, which is important as ectopic hyperfunctional thyroid has been reported in 4 to 23% 
of hyperthyroid cats.10,11 Complications can encompass iatrogenic hypoparathyroidism (6% 
5 
 
of patients in one study), recurrent laryngeal nerve damage and incomplete surgical 
resection.12 Additional risk exists in anaesthetising older feline patients with co-morbidities 
such as chronic kidney disease (CKD) and thyrotoxic cardiomyopathy.12 Overall 2% post-
operative mortality has been reported.12 Reported recurrence rates are 5 to 11% using 
various surgical techniques.12,13 Anti-thyroid drugs can be an effective option but do not 
prevent progression of the underlying pathological process in the thyroid.14,15 Therapeutic 
efficacy is also highly dependent on compliance with daily dosing.14,16 Adverse effects 
have been reported in 18% of patients receiving methimazole including anorexia, vomiting, 
lethargy, and less commonly, self-induced facial excoriation, cytopenias, 
lymphadenomegaly hepatopathy and myasthenia gravis.17,18 The prevalence of side effects 
using carbimazole is reported to be lower.19,20 
 
A recent survey of general practice veterinarians in the United Kingdom (UK) evaluated 
their approaches to management and monitoring of feline hyperthyroidism.21 In the UK, 
disadvantages of radioiodine have included limited availability and long waiting times, in 
addition to lengthy hospitalisation post-treatment due to radiation safety requirements (up 
to four to five weeks, until recently). In the UK survey, oral anti-thyroid medication was the 
most commonly preferred treatment option, however 59% of respondents agreed that 
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radioiodine was the gold standard for treatment of hyperthyroidism. 21 This highlights a 
discrepancy between the gold standard and the preferred treatment choice amongst 
veterinarians in the UK, raising the question of why such a discrepancy exists. 
 
Radioiodine treatment in Australia differs in several ways to that in the UK. In particular, 
access to radioiodine treatment facilities is greater, with 20 radioiodine treatment facilities 
(https://madmimi.com/p/525d16 lists treatments facilities in Australia) across five of six 
Australian states (servicing a human population of 25 million people) and generally shorter 
post-treatment hospitalisation, typically five to seven days. As a result, we hypothesised 
that radioiodine may be more widely utilised amongst Australian veterinarians and more 
widely accepted as the gold standard treatment, compared to the UK.   
 
This study aimed to evaluate how Australian veterinarians approach management of feline 
hyperthyroidism and compare these results to the UK survey. 
 
Materials and methods 
A survey of Australian general practitioners was modelled on the previous UK survey.21 A 
list of veterinary practices that treat cats in the Australian Capital Territory (ACT), New 
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South Wales (NSW), Northern Territory (NT), Queensland, South Australia (SA), 
Tasmania, Victoria and Western Australia (WA) was compiled using several directories, 
including the Australian business telephone directory and any state registers of veterinary 
practices. An invitation to participate in the survey was sent to each veterinary practice 
(including branches) by e-mail or post (if an e-mail address was unavailable), including a 
request to forward survey information to all veterinarians in the practice. A total of 1,705 
invitations were sent by email (ACT [26], NSW [527], NT [17], Queensland [368], SA 
[124], Tasmania [46], Victoria [401] and WA [196]) and 392 invitations by post (ACT [5], 
NSW [99], NT [1], Queensland [144], SA [23], Tasmania [8], Victoria [84] and WA [28]). 
Reminder e-mails were sent after one, three and four to five weeks. Reminders were not 
sent to postal recipients due to cost constraints. An iPad mini™ and three $100 textbook 
vouchers were offered as inducements for participation (winners were determined by 
ballot). 
 
The questionnaire, hosted by the University of Bristol Online Survey Program, was based 
on that performed by Higgs et al,21 with minor amendments to ensure appropriateness for 
Australian veterinarians. It comprised 32 questions divided into sections including: (i) 
general information on approach to management of hyperthyroidism, (ii) management of 
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hyperthyroidism with anti-thyroid drugs, (iii) radioiodine treatment, (iv) surgical treatment 
of hyperthyroidism and (v) respondent demographic information. At the time of the survey, 
the prescription diet (Hill’s y/d®) had not been released in Australia and as such was not 
included in questions. We elected to use the same survey platform to minimise differences 
due to data acquisition. 
 
Data were entered into a Microsoft Excel (Microsoft Office 15) spreadsheet and analysed 
using a statistical software package (Minitab version 17). Categorical and quantitative 
responses were analysed using descriptive statistics. Specific categorical responses were 
compared using χ2 and odds ratio testing of cross-tabulated data. For all tests, P values 
<0.05 were considered significant. 
 
Results 
Demographics 
There were a total of 546 respondents (Table 1), representing approximately 6% of 
registered veterinarians in Australia (9,782 veterinarians were registered in Australia in 
2012).22  Of these, 73% were female and 27% were male. Respondents had obtained 
veterinary training from the University of Sydney (n=147; 27%), University of Melbourne 
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(n=135; 25%), University of Queensland (n=122; 22%), Murdoch University (n=62; 11%), 
Charles Sturt University (n=10; 2%), University of Adelaide (n=5; 1%) and James Cook 
University (n=4; 1%), with remaining respondents having trained overseas (n=61; 11%). 
The median year of graduation was 2000 (range 1958 to 2014). The median number of 
veterinarians working in each veterinary practice was 3 (range 1 to 50). The median 
estimated percentage of the working day spent with cats was 30% (range 1 to 100%). In the 
practice where the respondent was working, 37% (n=202) had at least one person with post-
graduate qualifications in small animal or feline medicine and 23% (n=123) in surgery. 
 
Table 1.  Number and percentages of survey respondents from Australian states and 
territories. 
 
 
Management of feline hyperthyroidism 
 
State or territory 
Number of 
respondents (%) 
Australian Capital 
Territory 
18 (3) 
New South Wales 156 (29) 
Northern Territory 1 (0.2) 
Queensland 93 (17) 
South Australia 46 (8) 
Tasmania 19 (3) 
Victoria 170 (31) 
Western Australia 43 (8) 
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In the previous six months, 72% of veterinarians (392/546) had diagnosed one to five cats 
with hyperthyroidism.  Ninety-nine (18%) had diagnosed six to 10 cases, 28 (5%) had 
diagnosed 11 or more, while 27 (5%) had not diagnosed any. Preferred long-term treatment 
options were oral anti-thyroid medications (n=223; 41%), radioiodine (n=210; 38%), 
transdermal methimazole (n=82; 15%) and thyroidectomy (n=20; 4%). Veterinarians in 
WA were significantly less likely to prefer radioiodine (odds ratio [OR]=0.03; 95% 
confidence interval [CI] 0.00, 0.24; P<0.001) and significantly more likely to choose anti-
thyroid medications (OR=7; 95% CI 3, 17; P<0.001). When cost was removed as a 
consideration, 425 veterinarians (78%) chose radioiodine as their preferred long-term 
treatment; this was significantly greater than the proportion who preferred radioiodine 
when cost was a consideration (P<0.001). Of remaining respondents, preferred treatments 
were oral anti-thyroid medication (n=61; 11%), transdermal methimazole (n=30; 5%) and 
thyroidectomy (n=25; 5%) when cost was not a factor.  
 
Most veterinarians (406/546; 74%) indicated they did not have a practice policy for 
managing hyperthyroidism. Of those that did, 61 (44%) indicated their practice policy was 
long-term anti-thyroid medications, 45 (32%) was referral for radioiodine, 17 (12%) for in-
house radioiodine and five (4%) for thyroidectomy. The importance of various factors to 
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veterinarians when formulating a long-term management plan is provided in Table 2. Data 
from eight respondents were excluded from analysis due to an initial computer error that 
affected data collection for this question alone. 
 
 
 
Degree of importance of each factor 
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Table 2. Degree of importance of various factors when formulating a long-term plan 
for management of feline hyperthyroidism. Counts are provided, with percentage of 
total respondents in brackets (n=538). 
 
Anti-thyroid medication  
The majority of respondents (500/546; 92%) used anti-thyroid drugs as initial treatment for 
hyperthyroidism, either prior to curative treatment or for long-term term medical 
management, with oral carbimazole (Neomercazole®) used most commonly (244/546; 
  
 
Factor 
Not at all 
important  
(%) 
Not very 
important  
(%) 
Not sure 
(%) 
Important 
(%) 
Very 
important 
(%) 
Age of the cat  30 (5) 111 (20) 16 (3) 311 (57) 78 (14) 
Co-morbid disease  0 (0) 3 (0.6) 4 (0.7) 184 (34) 355 (65) 
Ease of drug 
administration  
1 (0.2) 6 (1) 1 (0.2) 222 (41) 316 (58) 
Owner compliance 
with medications  
0 (0) 3 (0.6) 2 (0.4) 183 (34) 358 (66) 
Cost of treatment  1 (0.2) 50 (9) 28 (5) 356 (65) 111 (20) 
Cost of any required 
monitoring  
5 (0.9) 83 (15) 38 (7) 364 (67) 56 (10) 
Whether the pet is 
insured  
118 (22) 240 (44) 92 (17) 76 (14) 20 (4) 
Risk of drug side 
effects  
7 (1) 82 (15) 44 (8) 345 (63) 68 (12) 
Risk of surgical 
complications  
26 (5) 58 (11) 69 (13) 258 (47) 135 (25) 
Ease of referral for 
radioiodine  
36 (7) 84 (15) 46 (8) 266 (49) 114 (21) 
Indoor v outdoor cat  154 (28) 250 (46) 74 (14) 61 (11) 7 (1) 
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49%), followed by methimazole (Felimazole™, Dechra Veterinary Products) (109/546; 
22%), transdermal methimazole (17/546; 14%), compounded oral methimazole or 
carbimazole (16/546; 3%) and carbimazole sustained-release tablets (Vidalta™, MSD 
Animal Health) (10/546; 2%). Remaining respondents (50/546; 10%) had no specific 
preference.  
 
With regard to monitoring cats receiving anti-thyroid medications, 328/546 respondents 
(60%) designed their own monitoring protocol based on their perception of patient needs, 
130 (24%) followed a practice policy and were comfortable that this was the best approach, 
33 (6%) designed their own monitoring protocol based on owner preference and 31 (6%) 
designed their monitoring protocol based on manufacturer datasheet guidelines. Some 
respondents (19; 3.5%) indicated they follow a practice protocol but would prefer more 
frequent monitoring, while 5 (1%) indicated they did not believe any monitoring apart from 
physical examination was necessary.  A summary of the frequency of monitoring various 
parameters in a hypothetical hyperthyroid patient is provided in Table 3.  Of respondents 
selecting other in relation to this question, most indicated their frequency of assessment was 
made on a case-by-case basis. 
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Table 3. Frequency of assessment of physical examination and laboratory parameters 
when respondents were asked the following question: “You have recently diagnosed 
hyperthyroidism in a 12 year old cat and prescribed anti-thyroid tablets. Which of the 
following parameters would you routinely use to monitor the patient and how often?” 
Counts are provided, with percentage of total respondents in brackets (n=546). 
 
 
 
Variable 
Monitoring in early 
stages of treatment (%) 
Frequency of assessment once stabilised 
(%) 
 
Not 
assessed 
(%) 
In the first  
3-4 weeks 
In the 2nd-
6th months 
Every 3 
months 
Every 6 
months 
Yearly  Other 
Body  
weight (kg) 
419 (78) 264 (49) 165 (31) 299 (56) 56 (10) 13 (2) 4 (0.7) 
Serum TT4 
concentration 
446 (83) 246 (46) 75 (14) 356 (66) 69 (13) 23 (4) 2 (0.4) 
Renal analytes 
(urea, 
creatinine, 
phosphate) 
403 (75) 199 (37) 61 (11) 304 (57) 86 (16) 36 (7) 8 (1) 
Liver enzymes 
activities (ALP, 
ALT) 
299 (56) 157 (29) 40 (7) 226 (42) 119 (22) 26 (5) 40 (7) 
PCV 258 (48) 119 (22) 27 (5) 191 (36) 104 (19) 23 (4) 89 (17) 
Complete blood 
count 
276 (51) 115 (21) 24 (4) 212 (39) 156 (29) 25 (5) 57 (11) 
Full 
biochemistry 
profile 
261 (49) 102 (19) 27 (5) 185 (34) 180 (33) 28 (5) 54 (10) 
Blood pressure 263 (49) 131 (24) 66 (12) 195 (36) 41 (8) 43 (8) 147 (27) 
In-house  
Urinalysis 
321 (60) 141 (26) 63 (12) 219 (41) 100 (19) 42 (8) 52 (10) 
Urinalysis 
externally 
(including 
UPCR) 
54 (10) 28 (5) 11 (2) 41 (8) 38 (7) 95 (18) 278 (52) 
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ALT alanine aminotransferase; ALP alkaline phosphatase; PCV packed cell volume; 
TT4 total T4; UPCR urine protein to creatinine ratio 
 
 
During therapy, 274/546 respondents (50%) aimed for total T4 concentration (TT4) to be 
anywhere in the laboratory reference interval (RI), 186 (34%) aimed for TT4 in the bottom 
half of the RI and 68 (12%) aimed for the upper half of the RI. One respondent (0.2%) 
aimed for TT4 to be just above the RI. In contrast, when there was pre-existing CKD, 244 
respondents (45%) aimed for TT4 in the upper half of the RI and 84 respondents (15%) for 
TT4 to be just above the RI. These proportions were significantly different to the 
proportion of respondents aiming for TT4 in the upper half of the RI or just above the RI 
when pre-existing CKD was absent (OR 3; 95% CI 2, 5; P<0.001). Of remaining 
respondents, 98 (18%) indicated that the presence of CKD did not affect their target TT4 
concentration, 65 (12%) aimed for TT4 concentration to be in the lower half of the RI and 
46 (8%) only aimed to ensure the cat was not hypothyroid. Nine respondents (2%) did not 
monitor renal analytes in hyperthyroid cats. 
  
Adverse reactions had been observed by 40% of veterinarians (217/546) in the previous 12 
months (Table 4). Of veterinarians who had seen adverse reactions, 182/217 (84%) had not 
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reported them to the AVPMA or drug manufacturer. The most common ‘other’ adverse 
reactions identified were skin reactions to transdermal formulations and diarrhoea. 
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Table 4. Frequency and percentages of adverse reactions to anti-thyroid medications 
observed by respondents (n=217). Counts are provided, with percentage of total 
respondents in brackets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Surgical thyroidectomy 
Only 119/546 veterinarians (22%) had performed one or more thyroidectomies on cat(s) 
with hyperthyroidism. Of these, 51 (43%) did not routinely submit resected thyroid tissue 
for histopathologic assessment, with 28/119 (24%) submitting 100% of samples, 26/119 
(22%) submitting 1-20% of samples, and 14/119 (12%) submitting 21-99% of samples. Of 
samples submitted for histology, thyroid adenocarcinoma was diagnosed in no instance by 
  
Adverse reaction 
Count 
(%) 
Vomiting 143 (66) 
Anorexia 98 (45) 
Head and neck pruritus 57 (26) 
Azotaemia 48 (22) 
Elevated liver enzymes 45 (21) 
Neutropenia 21 (10) 
Leukopenia 16 (7) 
Anaemia 12 (6) 
Jaundice 7 (3) 
Thrombocytopenia 5 (2) 
Lymphadenomegaly 4 (2) 
Other 8 (4) 
Total 464 
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27 respondents (43%), 1-10% of cases by 20 respondents (32%) and 11-50% of cases by 10 
respondents (16%). In cases undergoing bilateral thyroidectomy, recurrence of 
hyperthyroidism was noted in no cases by 39% of respondents (46/119), in 1-10% of cases 
by 23% of respondents (27/119) and in more than 11% of cases by 7% of respondents 
(8/119). Thirty-eight respondents (32%) had never been involved in bilateral 
thyroidectomy. 
 
Most respondents believed that less than 10% (n=305; 56%) or 10-20% (n=173; 32%) of 
cats had ectopic thyroid tissue. Nuclear scintigraphy was uncommonly offered, with 51% 
(72/141) of veterinarians never offering it before surgery.  
 
Radioiodine treatment 
Eighty-two percent (447/546) of respondents either agreed or strongly agreed that 
radioiodine is the ‘gold standard treatment’ for hyperthyroidism, while 4.4% (n=24) either 
disagreed or strongly disagreed with this statement. The remainder (n=75; 14%) were 
unsure. With regard to the percentage of cases in which radioiodine was offered to clients, 
214/546 (39%) respondents offered it in 100% of cases, 118 (22%) in 81-99% of cases, 66 
(12%) in 51-80% of cases and 148 (27%) in less than 50% of cases. The median number of 
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cases respondents had either personally treated with or referred for radioiodine treatment 
was two (range 0 to 800). The closest radioiodine treatment centre was less than 50 km 
from 285 respondents (52%), 51 to 100 km away for 68 respondents (12%), from 100 to 
300 km for 90 respondents (16%) and >301 km away for 82 respondents (15%). The 
remainder (21/546; 4%) did not know the location of their closest radioiodine treatment 
centre.  
 
A summary of factors impacting respondents’ likelihood of offering radioiodine are 
provided in Table 5, while the degree of concern caused to clients by various factors as 
assessed by the veterinarian are explained in Table 6. In relation to the likelihood of 
referring a hyperthyroid cat for radioiodine treatment, 399/546 respondents (73%) indicated 
they were either highly or quite likely to do this, while 88/546 respondents (16%) were 
either highly or quite unlikely to do this. The remainder were unsure (n=59; 11%). 
 
Most veterinarians (323/546; 59%) considered that greater than 80% of cats were cured by 
standard doses of radioiodine, with 76 respondents (14%) selecting 61-80% of cats as being 
cured.  The percentage of cats cured by standard doses of radioactive iodine was unknown 
by 119/546 respondents (22%).  
20 
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Table 5.  The effects of various factors on the likelihood of veterinarians offering 
radioiodine treatment to clients. Counts are provided, with percent of total 
respondents in brackets (n=546). 
  
 
 
 Factor 
Definitely 
would not 
offer (%) 
Quite 
unlikely to 
offer (%) 
 
Not sure 
(%) 
Quite 
likely to 
offer (%) 
Definitely 
would 
offer (%) 
Young cat e.g. 10 years or less  9 (2) 11 (2) 27 (5) 104 (19) 395 (72) 
Old cat e.g. >15 years  32 (6) 133 (24) 67 (12) 158 (29) 156 (29) 
Co-existing renal disease  83 (15) 205 (38) 107 (20) 97 (18) 54 (10) 
Co-existing/secondary heart 
disease  
44 (8) 141 (26) 127 (23) 131 (24) 103 (19) 
Poor owner and/or cat 
compliance for drug 
administration  
10 (2) 26 (5) 21 (4) 154 (28) 335 (61) 
Good owner and/or cat 
compliance for drug 
administration  
11 (2) 74 (14) 40 (7) 176 (32) 245 (45) 
Poor response to drug therapy  8 (1) 28 (5) 48 (9) 160 (29) 302 (55) 
Good response to drug therapy  16 (3) 137 (25) 56 (10) 134 (25) 203 (37) 
Recurrence of disease after 
thyroidectomy  
11 (2) 18 (3) 108 (20) 130 (24) 279 (51) 
Cat is insured  7 (1) 4 (0.7) 52 (10) 147 (27) 336 (62) 
Cat is not insured  9 (2) 44 (8) 78 (14) 148 (27) 267 (49) 
Suspected ectopic thyroid tissue  8 (1) 13 (2) 114 (21) 143 (26) 268 (49) 
<2 hours travel to nearest 
radioiodine centre  
8 (1) 11 (2) 52 (10) 160 (29) 315 (58) 
>2 hours travel to nearest 
radioiodine centre  
17 (3) 97 (18) 82 (15) 143 (26) 207 (38) 
Long waiting list (>3 months)  16 (3) 96 (18) 84 (15) 153 (28) 197 (36) 
No waiting list for radioiodine  9 (2) 7 (1) 74 (14) 158 (29) 298 (55) 
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Table 6. The degree of concern caused to clients by various factors relating to 
radioiodine treatment, as assessed by the veterinarian. Counts are provided, with 
percent of total respondents in brackets (n=546). 
 
Factor 
No concern 
(%) 
Little concern 
(%) 
Great concern 
(%) 
Cost of treatment 7 (1) 92 (17) 446 (82) 
Distance of travel to the 
radioiodine treatment facility 
68 (13) 212 (39) 264 (49) 
Risk of radiation exposure 70 (13) 344 (63) 128 (24) 
Potential for development of 
side effects of the treatment 
39 (7) 315 (58) 189 (35) 
Potential for development of 
co-morbid disease during 
44 (8) 310 (57) 187 (35) 
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Laboratory testing of serum TT4 concentrations 
Most veterinarians (352/546; 64%) were aware of the different laboratory methods 
available for monitoring TT4. An external laboratory was used for measuring TT4 
concentration by 449/546 respondents (82%), with remaining respondents using in-house 
testing. Half of respondents (225/449; 50%) used an external laboratory where TT4 is 
measured by enzyme immunoassay. 
 
Discussion 
Feline hyperthyroidism is commonly diagnosed by Australian veterinarians. Radioiodine 
was a preferred long-term treatment option by more than a third (38%) of respondents, 
which increased to 78% when cost was removed as a consideration. However, anti-thyroid 
isolation 
Possibility of the cat being 
unhappy away from home 
28 (5) 179 (33) 338 (62) 
Possibility of development of 
anorexia away from home 
34 (6) 272 (50) 235 (43) 
Possibility of the owner or 
other family members missing 
the cat 
63 (12) 269 (50) 211 (39) 
Possibility other pets may miss 
the cat 
148 (27) 311 (58) 81 (15) 
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medications were the most frequently used treatment modality and twice daily carbimazole 
preferred by 49% of surveyed veterinarians. Surgical thyroidectomy was rarely performed. 
 
Greater preference for radioiodine amongst Australian veterinarians contrasts with the UK 
survey. In that survey, only 6% of respondents preferred radioiodine treatment for long-
term management, rising to 41% when cost was not considered.21 Factors including reduced 
hospitalisation times compared to those historically in the UK and more widespread 
availability of treatment facilities in Australia may have led to a more positive attitude to 
radioiodine. In our survey, the impact of accessibility was highlighted by significantly 
reduced preference for this treatment modality amongst WA veterinarians, where no such 
facilities currently exist.   
 
In spite of widespread preference for radioiodine treatment, Australian veterinarians treated 
or referred very few cases for radioiodine treatment (median 2). This suggests that barriers 
to radioiodine utilisation persist in Australia. Indeed, 22% of veterinarians were unaware of 
the success rates of radioiodine treatment and an additional 19% underestimated the 
percentage of cats cured by standard doses of radioiodine. As a result, veterinarians may 
offer referral for radioiodine, but may not do so in a sufficiently compelling manner for 
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clients to opt for this treatment. Similarly to Higgs and colleagues’ survey,21 compliance 
with treatment, ease of drug administration, co-morbidities, treatment expense and 
monitoring emerged as important factors when developing long-term plans for hyperthyroid 
cats. Importantly, 82% of veterinarians reported they perceived radioiodine treatment cost 
was of great concern to clients. This contrasts with a survey of UK owners where cost had 
low impacts on the selected treatment, although that may be due to greater adoption of pet 
insurance in this jurisdiction.9  Veterinarians may also overemphasise the role of cost in 
owner decision-making. While there is some variation in treatment expenses for 
hyperthyroidism, typically the cost of curative treatment approximates one year of daily 
anti-thyroid medication and monitoring. Therefore, on a cost basis, curative treatment 
should be strongly considered where a cat is expected to live more than 12 months post-
diagnosis.14,23  
 
Despite the advantages of radioiodine, anti-thyroid therapy was used by more than 90% of 
veterinarians in our survey, either for long-term management or prior to curative treatment. 
Problematically, anti-thyroid drugs fail to treat the underlying pathologic process. As a 
result, there is propensity for the primary process to progress, with eventual refractoriness 
to medical management and sometimes malignant transformation. Indeed, the prevalence of 
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thyroid carcinoma is reported to increase from less than 5% to 19% in cats managed with 
anti-thyroid medication for more than four years.14,15 Cats treated with methimazole have 
shorter survival times than those treated with radioiodine; client compliance with drug 
administration, poor titration of therapy and drug toxicoses have been hypothesised to 
account for this observation.8 While the reversibility of anti-thyroid medication allows 
assessment of the effects of restoring euthyroidism on renal function,14 the importance of 
trialling this before definitive treatment is now being challenged, particularly when pre-
existing azotaemia is absent. A recent study showed that hypothyroid cats that become 
azotaemic following treatment have shorter survival times.24 Emphasis should therefore be 
placed on carefully monitoring thyroid status after definitive therapy to avoid 
hypothyroidism by pre-emptive replacement therapy with thyroxine, where necessary.  
 
The most commonly used anti-thyroid medication was twice daily carbimazole, rather than 
licensed methimazole (Felimazole™) or sustained-release once daily carbimazole 
(Vidalta™). This likely reflects familiarity as the latter two medications have only recently 
become available in Australia. However, it serves to emphasise the need for veterinarians to 
remain abreast of new drugs, particularly those that have potential to improve compliance 
by reducing administration frequency. Transdermal methimazole was often used by 
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respondents to our survey. It is thought to improve client compliance,14,25 but a study 
evaluating long-term transdermal methimazole use found 17% of owners admitted not 
treating their cat regularly, suggesting compliance may still be suboptimal.26 Adverse 
reactions of anti-thyroid medications were consistent with previous reports.14 Interestingly, 
few veterinarians had reported adverse reactions to the manufacturer or relevant authority, 
suggesting significant under-reporting exists, similar to the UK study.21  
 
Surgical thyroidectomy had been performed by approximately one-fifth of respondents in 
our survey, but only 4% of veterinarians selected thyroidectomy as their preferred 
treatment, compared to 28% in the UK.21 Barriers to performing thyroidectomy in general 
practice, including in Australia, may include concern regarding anaesthetic risks associated 
with co-morbid conditions such as CKD or cardiomyopathy, limited access to nuclear 
scintigraphy to assess the location of hyperfunctional thyroid tissue, limited experience 
performing the surgery and absence of adequate post-operative monitoring to manage 
complications such as hypocalcaemia. The majority of veterinarians were aware that 
ectopic hyperfunctional thyroid tissue could be present in 4 to 23% of hyperthyroid 
cats.10,11  
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Evaluation of serum TT4 is essential for diagnosis and monitoring of hyperthyroidism. 
Methods for measuring TT4 include radioimmunoassay (RIA), chemiluminescent enzyme 
immunoassays (CEIA) and enzyme immunoassays (EIA; also available as in-house assays), 
with all but RIA being relatively inexpensive and widely available.27 While CEIA provides 
similar results to the gold standard RIA, EIA has higher rates of false positive and false 
negative results and tends to underestimate TT4, leading to discordant results in 24% of 
cases.27 In Australia, the major veterinary laboratories use different techniques and 
therefore results cannot be compared between laboratories. Veterinarians must be aware of 
test methodologies and their varying precision at diagnosing and monitoring hyperthyroid 
cats using TT4. The in-house EIA has also been evaluated with conflicting reports on its 
usefulness for TT4 measurement, but one study suggested its accuracy to be lower than 
other methodologies.27-29 With in-house EIAs used by 18% of veterinarians in our survey, 
and widespread use of a commercial laboratory that uses EIA, many veterinarians may be 
unaware of the potential for spurious and misleading results. We advise utilising 
laboratories that use the CEIA methodology, as has been recommended by Peterson.27 
Although generally accepted that the treatment goal when using anti-thyroid medications is 
for TT4 concentration to be within the lower half of the RI,14 50% of respondents aimed for 
TT4 to be anywhere within the RI and 12% aimed for it to be in the upper half of the RI (in 
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the absence of CKD). This suggests that many cats may be inadequately treated and 
consequently may continue to experience the adverse pathophysiological effects of 
hyperthyroidism. While there was a statistically significant increase in the number of 
respondents aiming for TT4 to be in the upper half or above the reference interval when 
CKD was present, many veterinarians do not appear to be aware of current advice 
regarding management of hyperthyroid cats with concurrent renal azotaemia, which is for 
TT4 to be maintained in the lower half of the reference interval, but to avoid 
hypothyroidism; only 8% aimed to ensure that the patient did not become hypothyroid.  
 
A recent review of best practice for monitoring cats managed with anti-thyroid medication 
emphasised regular history taking, serial examinations, bodyweight and body condition 
score estimations, TT4 concentrations measured by the same laboratory, renal analytes and 
systolic blood pressure.14 In our survey, monitoring in the initial few weeks of therapy was 
generally adequate. However, during maintenance therapy, blood pressure monitoring was 
significantly underutilised, with less than half of clinicians complying with monitoring 
recommendations.14 Similar observations were made in the survey by Higgs et al.21 Regular 
assessment of hyperthyroid cats after treatment is important to prevent devastating 
hypertensive sequelae such as retinal or intracranial haemorrhage as well as detrimental 
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effects on renal function. Hypertension is present in 14 to 23% of hyperthyroid cats at 
diagnosis, though has been reported in up to 87% of cats in one study, and importantly, 
23% of initially normotensive cats develop hypertension following restoration of 
euthyroidism.30-32 Hypertension has been correlated with reduced survival times in a 
retrospective study of cats treated primarily with anti-thyroid medications and/or 
thyroidectomy.33 
 
Practice policies for management of feline hyperthyroidism were reported by 
approximately one-quarter of veterinarians in our survey. The most common practice 
protocol was for long-term management with anti-thyroid medications. Although there may 
be valid reasons for this, it underscores the importance of continuing to raise awareness of 
best practice for managing hyperthyroidism and consideration of tailoring long-term 
treatment plans to the individual patient and owner. For non-azotaemic cats expected to live 
more than 12 months after diagnosis, practice policies for long-term anti-thyroid 
medications may be promoting suboptimal treatment associated with shorter survival times, 
likely reduced quality of life and increased risk of development of thyroid carcinomas.8,15 
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The current study suffers from some limitations, similar to those reported by Higgs and 
collaborators.21 Inherent limitations of surveys include difficulty with recall, leading to 
inaccurate responses and bias in responding to the questions by predicting the desired 
response rather than reflecting the usual practices of the respondent.34 The distribution of 
veterinarians in the Australian states and territories was largely similar to the percentages of 
respondents from these locations in our survey, suggesting the survey may be 
representative of veterinarians across Australia.35 In addition to this, the survey was 
conducted prior to the release of the iodine-restricted prescription diet in Australia and as a 
result, it is not possible at this time to determine how it will influence treatment decisions 
for hyperthyroid cats. 
 
Conclusions 
Despite radioiodine treatment being more commonly preferred amongst Australian 
veterinarians compared to those in the UK, practical barriers persist that limit its utilisation, 
particularly high initial cost, misconceptions regarding efficacy and availability of referral 
centres in some regions of Australia.  When discussing treatment options with owners, 
veterinarians should emphasise the significant advantages of radioiodine treatment and its 
overall cost effectiveness in cats expected to live greater than 12 months post-diagnosis.  
32 
 
Long-term anti-thyroid medication was the most frequently preferred treatment modality 
for hyperthyroid cats in our survey. Anti-thyroid medications were also commonly used on 
a trial basis before definitive management. Current evidence suggests that this may be 
unnecessary in cats that are non-azotaemic prior to radioiodine treatment, though should 
still be considered prior to thyroidectomy so anaesthesia is performed in a stable patient. 
Monitoring practices of veterinarians in our survey were similar to those in the UK survey 
and may be improved by enhanced emphasis on regular blood pressure determination and 
appropriately targeting TT4 concentrations while using carbimazole or methimazole in both 
non-azotaemic and azotaemic hyperthyroid cats. Practice policies for management of feline 
hyperthyroidism, particularly where they advocate long-term medical management, should 
be discouraged in favour of tailoring management of hyperthyroidism based on patient and 
client factors with reference to current literature.   
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